CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India
- PMID: 40090349
- DOI: 10.1016/S2352-3026(25)00040-7
CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India
Conflict of interest statement
MR reports grants and personal fees from viTToria Bio; non-financial support from Beckman Coulter and ORFLO; personal fees from GSK, Bristol Myers Squibb, Sana, NanoString, GLG, and Guidepoint; grants from AbClon and ONI; and multiple patents on CAR T immunotherapy managed by the University of Pennsylvania that are pending, issued, licensed, and with royalties paid from viTToria Bio, Novartis, and Tmunity. LP declares no competing interests.
Comment on
-
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.Lancet Haematol. 2025 Apr;12(4):e282-e293. doi: 10.1016/S2352-3026(24)00377-6. Epub 2025 Mar 13. Lancet Haematol. 2025. PMID: 40090352 Clinical Trial.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
